126 related articles for article (PubMed ID: 25980494)
1. Cyr61 as mediator of Src signaling in triple negative breast cancer cells.
Sánchez-Bailón MP; Calcabrini A; Mayoral-Varo V; Molinari A; Wagner KU; Losada JP; Ciordia S; Albar JP; Martín-Pérez J
Oncotarget; 2015 May; 6(15):13520-38. PubMed ID: 25980494
[TBL] [Abstract][Full Text] [Related]
2. A novel anti-Cyr61 antibody inhibits breast cancer growth and metastasis in vivo.
Lin J; Huo R; Wang L; Zhou Z; Sun Y; Shen B; Wang R; Li N
Cancer Immunol Immunother; 2012 May; 61(5):677-87. PubMed ID: 22048717
[TBL] [Abstract][Full Text] [Related]
3. The matricellular protein CCN1 suppresses hepatocarcinogenesis by inhibiting compensatory proliferation.
Chen CC; Kim KH; Lau LF
Oncogene; 2016 Mar; 35(10):1314-23. PubMed ID: 26028023
[TBL] [Abstract][Full Text] [Related]
4. The Histone Methyltransferase Inhibitor BIX01294 Inhibits HIF-1α Stability and Angiogenesis.
Oh SY; Seok JY; Choi YS; Lee SH; Bae JS; Lee YM
Mol Cells; 2015 Jun; 38(6):528-34. PubMed ID: 26013382
[TBL] [Abstract][Full Text] [Related]
5. Identification and evaluation of network modules for the prognosis of basal-like breast cancer.
Hallett RM; Cockburn JG; Li B; Dvorkin-Gheva A; Hassell JA; Bane A
Oncotarget; 2015 Jul; 6(19):17713-24. PubMed ID: 25991675
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Increased Invasiveness of Breast Cancer Cells With Acquired Tamoxifen Resistance by Suppression of CYR61.
Bauerschmitz G; Hüchel S; Gallwas J; Gründker C
Cancer Genomics Proteomics; 2023; 20(6):531-538. PubMed ID: 37889058
[TBL] [Abstract][Full Text] [Related]
7. Proteins Found in the Triple-Negative Breast Cancer Secretome and Their Therapeutic Potential.
McHenry PR; Prosperi JR
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768435
[TBL] [Abstract][Full Text] [Related]
8. Depletion of CCN1/CYR61 reduces triple-negative/basal-like breast cancer aggressiveness.
Espinoza I; Kurapaty C; Park CH; Vander Steen T; Kleer CG; Wiley E; Rademaker A; Cuyàs E; Verdura S; Buxó M; Reynolds C; Menendez JA; Lupu R
Am J Cancer Res; 2022; 12(2):839-851. PubMed ID: 35261806
[TBL] [Abstract][Full Text] [Related]
9. The Relevance of the SH2 Domain for c-Src Functionality in Triple-Negative Breast Cancer Cells.
Mayoral-Varo V; Sánchez-Bailón MP; Calcabrini A; García-Hernández M; Frezza V; Martín ME; González VM; Martín-Pérez J
Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33530373
[TBL] [Abstract][Full Text] [Related]
10. Targeting
Alcalá S; Mayoral-Varo V; Ruiz-Cañas L; López-Gil JC; Heeschen C; Martín-Pérez J; Sainz B
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33050159
[TBL] [Abstract][Full Text] [Related]
11. Dexamethasone and lenvatinib inhibit migration and invasion of non-small cell lung cancer by regulating EKR/AKT and VEGF signal pathways.
Zhang D; Zhang Y; Cai Z; Tu Y; Hu Z
Exp Ther Med; 2020 Jan; 19(1):762-770. PubMed ID: 31853327
[TBL] [Abstract][Full Text] [Related]
12. RU486 Metabolite Inhibits CCN1/Cyr61 Secretion by MDA-MB-231-Endothelial Adhesion.
Yu S; Yan C; Wu W; He S; Liu M; Liu J; Yang X; Ma J; Lu Y; Jia L
Front Pharmacol; 2019; 10():1296. PubMed ID: 31824306
[TBL] [Abstract][Full Text] [Related]
13. Intramitochondrial Src kinase links mitochondrial dysfunctions and aggressiveness of breast cancer cells.
Djeungoue-Petga MA; Lurette O; Jean S; Hamel-Côté G; Martín-Jiménez R; Bou M; Cannich A; Roy P; Hebert-Chatelain E
Cell Death Dis; 2019 Dec; 10(12):940. PubMed ID: 31819039
[TBL] [Abstract][Full Text] [Related]
14. Multi-omic Dissection of Oncogenically Active Epiproteomes Identifies Drivers of Proliferative and Invasive Breast Tumors.
Wrobel JA; Xie L; Wang L; Liu C; Rashid N; Gallagher KK; Xiong Y; Konze KD; Jin J; Gatza ML; Chen X
iScience; 2019 Jul; 17():359-378. PubMed ID: 31336272
[TBL] [Abstract][Full Text] [Related]
15. c-Src inhibitor selectively inhibits triple-negative breast cancer overexpressed Vimentin in vitro and in vivo.
Lou L; Yu Z; Wang Y; Wang S; Zhao Y
Cancer Sci; 2018 May; 109(5):1648-1659. PubMed ID: 29575318
[TBL] [Abstract][Full Text] [Related]
16. In Vitro Validation of the Hippo Pathway as a Pharmacological Target for Canine Mammary Gland Tumors.
Guillemette S; Rico C; Godin P; Boerboom D; Paquet M
J Mammary Gland Biol Neoplasia; 2017 Sep; 22(3):203-214. PubMed ID: 28822004
[TBL] [Abstract][Full Text] [Related]
17. Clinical relevance of Cyr61 expression in patients with hormone-dependent breast cancer.
Mayer S; Erbes T; Timme-Bronsert S; Jaeger M; Rücker G; Kuf F; Stickeler E; Gitsch G; Hirschfeld M
Oncol Lett; 2017 Aug; 14(2):2334-2340. PubMed ID: 28789451
[TBL] [Abstract][Full Text] [Related]
18. Cyr61-positive cancer stem-like cells enhances distal metastases of pancreatic cancer.
Shi W; Zhang C; Chen Z; Chen H; Liu L; Meng Z
Oncotarget; 2016 Nov; 7(45):73160-73170. PubMed ID: 27705906
[TBL] [Abstract][Full Text] [Related]
19. Structural and Biochemical Basis for Intracellular Kinase Inhibition by Src-specific Peptidic Macrocycles.
Aleem S; Georghiou G; Kleiner RE; Guja K; Craddock BP; Lyczek A; Chan AI; Garcia-Diaz M; Miller WT; Liu DR; Seeliger MA
Cell Chem Biol; 2016 Sep; 23(9):1103-1112. PubMed ID: 27593110
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
